Corvus Pharmaceuticals
Latest round
- Series B
Last raised
- Sep 2015
Total raised
- $109M
Investors
- 11
About Corvus Pharmaceuticals
Founded in 2014, Corvus Pharmaceuticals, Inc. operates from Burlingame, California, and focuses on developing advanced therapies for conditions like cancer.99 mn in February 2021. The founder, Peter Thompson, has a history in the pharmaceuticals sector, although no other previous companies are noted.Corvus Pharmaceuticals focuses on developing innovative therapies aimed at treating immune diseases and cancer, emphasizing their lead product, soquelitinib. This first-in-class oral therapy selectively inhibits ITK (interleukin-2-inducible T-cell kinase), which plays a critical role in modulating immune responses. By targeting ITK, soquelitinib aims to enhance the effectiveness of immune system signaling pathways, offering potential benefits for patients suffering from various immune-related conditions and specific cancer types.Revenue generation for Corvus Pharmaceuticals is centered around their therapeutic product offerings, particularly soquelitinib. The company engages in business transactions primarily through partnerships with pharmaceutical distributors and healthcare providers. These transactions can involve direct sales agreements, where healthcare institutions procure the drug for patient use, or collaborative arrangements with larger pharmaceutical firms for joint development and commercialization efforts. Pricing structures are designed to reflect the value of the innovative treatment provided, with strategies tailored to accommodate different market conditions and healthcare reimbursement frameworks. The company has not publicly specified upcoming product launches or release dates but is likely to continue its research into new therapies that address unmet medical needs in oncology and immunology. Corvus also aims to explore expansion opportunities into additional markets in Europe and Asia, leveraging its existing partnerships to enhance market presence. The strategic direction includes maintaining a focus on innovation while broadening its therapeutic offerings to address a wider range of conditions by 2023.
Who invested in Corvus Pharmaceuticals
11 investors across 2 rounds
See all investors in Corvus Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Corvus Pharmaceuticals
Who invested in Corvus Pharmaceuticals?
Corvus Pharmaceuticals has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Corvus Pharmaceuticals raised?
Corvus Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Corvus Pharmaceuticals last raise money?
Corvus Pharmaceuticals's most recent round on record is a Series B, in Sep 2015.
What does Corvus Pharmaceuticals do?
Founded in 2014, Corvus Pharmaceuticals, Inc.
Where is Corvus Pharmaceuticals headquartered?
Corvus Pharmaceuticals is headquartered in Burlingame, US.
Which VCs invest in companies like Corvus Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Corvus Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Corvus Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.